Tyrosine News and Research

RSS

Gene linked to lower BMI points researchers toward a new obesity target

A review in Cardiology in Review highlights GPR75, a receptor for 20-HETE, as a promising therapeutic target for obesity and metabolic syndrome. Evidence from genetic studies, cell experiments, and mouse models suggests that blocking this pathway could influence weight gain, insulin resistance, hypertension, inflammation, and vascular dysfunction.

25 Jun 2026

Scientists uncover new molecular mechanism driving gastrointestinal stromal tumors

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract, with KIT mutations driving approximately 75% to 80% of cases.

23 Jun 2026

Trial identifies 4 grams a day as the tested safe level for L-tyrosine in healthy men

A randomized, crossover trial in healthy adult men found that 4 weeks of L-tyrosine supplementation at doses up to 4 g/day did not cause clinically meaningful changes in safety markers, diet, blood pressure, or body measures. The highest tested dose, 4 g/day, was identified as the no-observed-adverse-effect level under the study’s four-week conditions, although broader and longer-term studies are still needed.

23 Jun 2026

New human protein atlas maps how cancer rewires the body’s tissues

Researchers created a DIA-MS atlas of 13,609 proteins across 2,856 samples from fetal, healthy adult, paired non-tumor, and tumor tissues. The resource maps tissue-specific protein patterns, cancer-associated changes, organ-specific drug-toxicity signals, and candidate therapeutic targets.

21 Jun 2026

Review highlights TIGIT as a promising second-generation immunotherapy target

Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response rates.

5 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

Urine test may help identify autism risk in children

A simple urine test may help identify children at risk for autism sooner than current assessments - opening the door for earlier diagnosis and treatment, and better long-term outcomes for children who do have autism spectrum disorder.

26 May 2026

New computational pipeline improves effectiveness of pan-Ebola neutralizing antibodies

A team led by Professor Wei Yang at the National Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, has developed a computational-experimental pipeline that synergistically optimizes antibody framework regions (FR) and complementarity-determining regions (CDR).

24 May 2026

Study reveals cellular mechanisms driving resistance to targeted cancer therapies

Despite impressive innovations in medicine, most advanced-stage cancers still carry a grim prognosis. Developing more effective treatments requires a deeper understanding of the cellular processes that drive the formation and growth of common cancers.

20 May 2026

Real-world study compares leading ALK+ lung cancer treatments

A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted a head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer.

19 May 2026

Prenatal chemical mixtures may influence fetal growth and placental health

Common environmental chemicals could affect birthweight and placental function, according to a new study published in Environmental Science & Technology and led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by "la Caixa" Foundation. Conducted within the Barcelona Life Study Cohort (BiSC), the research underscores the importance of considering real-life exposure to complex chemical mixtures and highlights the role of angiogenic biomarkers in linking these exposures to fetal development.

17 May 2026

Tumor splicing burden predicts treatment response in kidney cancer

Researchers at City of Hope® and TGen (part of City of Hope) have identified a significant correlation between a tumor's "splicing burden" and its clinical response to treatment for metastatic renal cell carcinoma (mRCC).

5 May 2026

Finding new ways to mimic ketamine’s antidepressant effects

Weill Cornell Medicine investigators have "reverse engineered" ketamine's antidepressant effects to identify potential new strategies for treating depression.

4 May 2026

New blood filtering treatment safely extends pregnancy in severe preeclampsia

Cedars-Sinai Health Sciences University investigators have developed and successfully tested a new treatment for pregnant women with severe early preeclampsia, a leading cause of premature birth as well as maternal and fetal death.

27 Apr 2026

How next-generation proteomics is decoding the language of life

This review examines how next-generation protein sequencing and analysis technologies are expanding proteomics beyond the limits of mass spectrometry, especially for detecting proteoforms and analyzing proteins at single-molecule resolution. It highlights maturing fluorescence-based and nanopore-based platforms that could complement existing methods and deepen insight into protein sequence, structure, function, and modification states.

13 Apr 2026

Blocking nitric oxide suppresses tumor growth in aggressive pediatric neuroblastoma

The tumor begins before birth. Somewhere in the developing fetus, neural crest cells that should have matured into adrenal tissue or sympathetic ganglia take a wrong turn, and a child is born harboring a malignancy that may not declare itself for months.

7 Apr 2026

How could bisphenol A raise depression risk? Study identifies six key molecular targets

An integrative Translational Psychiatry study linked BPA exposure to major depressive disorder by identifying 571 shared targets and six core genes, with genetic, transcriptomic, docking, and mouse-model data supporting plausible mechanistic pathways. The strongest signals pointed to AKT1, SRC, PLCG2, and JAK3 as potential contributors, while EGFR appeared protective.

31 Mar 2026

Scientists turn plastic waste into Parkinson’s drug levodopa using engineered bacteria

Researchers engineered a two-strain microbial system that converts PET-derived terephthalic acid into levodopa, overcoming key bottlenecks in transport and enzyme inhibition. The proof-of-concept process achieves high yields under mild conditions and demonstrates a potential route for upcycling plastic waste into valuable pharmaceuticals.

17 Mar 2026

Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.

13 Mar 2026

A novel approach to improving survival in treatment-resistant cancers

Researchers at the National University of Singapore (NUS) have identified a protein called tyrosine phosphatase 1B (PTP1B) as a potential "switch" that can modulate a type of cancer cell death known as immunogenic cell death (ICD).

6 Mar 2026